Low Endotoxin Purified Anti-Human CD279/PD-1 Antibody [J110] (AGEL2093)
- SKU:
- AGEL2093
- Product Type:
- Antibody
- Antibody Type:
- Monoclonal Antibody
- Reactivity:
- Human
- Applications:
- FC
Frequently bought together:
Description
Product Title: | Low Endotoxin Purified Anti-Human CD279/PD-1 Antibody [J110] |
SKU: | AGEL2093 |
Size: | 50µg, 500µg, 1mg |
Clone No: | J110 |
Synonyms: | PDCD1;PD1;Protein PD-1;hPD-1; |
Host Species: | Mouse |
Reactivity: | Human |
Application: | FCM |
Isotype: | Mouse IgG1, κ |
Isotype Control: | AF/LE Purified Mouse IgG1, κ Isotype Control[MOPC-21] |
Form: | Liquid |
Conjugation: | None (AF/LE) |
Recommended Use: | Each lot of this antibody is quality control tested by flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. |
Swissprot: | Q15116 |
Gene ID: | 5133 |
Storage Buffer: | 0.2 μm filtered in PBS, pH 7.2. Azide Free (AF)/Low Endotoxin (LE): Contains no stabilizers or stabilizers. Endotoxin level is < 2 EU/mg as Determined by LAL gel clotting assay. |
Stability & Storage: | Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase. |
Background: | Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 and PD-L2 are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion. |